Ask AI
ProCE Banner Activity

CE / CME

The APP’s Guide to Patient-Centered Management of BTK Inhibitor Therapy in Lymphoma

Multimedia

In this certified on-demand webcast, an APP provides an in-depth overview of the role of BTK inhibitors in managing B-cell malignancies, including CLL, mantle cell lymphoma, and follicular lymphoma. Key considerations for APPs, from diagnosis and symptom recognition to therapy selection, adverse effect management, and strategies to improve patient education, adherence, and equitable access to care, are also highlighted.

Nurse Practitioners/Nurses: 1.00 Nursing contact hours, includes 1.00 hour of pharmacotherapy credit

Physician Assistants/Physician Associates: 1.00 AAPA Category 1 CME credit

Released: September 29, 2025

Expiration: March 28, 2026

Share

Provided by

Provided by Partners for Advancing Clinical Education (Partners) in partnership with Clinical Care Options, LLC.

ProCE Banner

Supporters

Supported by an educational grant from BeOne Medicines.

BeOne Medicines

Partners

Clinical Care Options, LLC

ProCE Banner

Target Audience

This activity is intended for nurse practitioners, physician associates, nurses, and other healthcare professionals who care for patients with lymphoma. 

Program Learning Goal

This activity aims to equip oncology APPs with the education, skills, and resources needed to provide optimal care to patients with B-cell lymphomas who are receiving or are eligible for BTK inhibitor therapy.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Describe how adverse event profiles and patient-specific factors influence the selection of BTK inhibitors in managing B-cell malignancies​

  • Discuss the role of biomarker-driven testing in informing BTK inhibitor therapy selection and guiding risk mitigation strategies​

  • Identify common patient-reported barriers to BTK inhibitor adherence and strategies—including patient education and digital health tools—to improve treatment continuity​

  • Explain key eligibility criteria for clinical trials investigating novel BTK inhibitors to support patient counseling and trial referral decisions

Disclosure

Partners for Advancing Clinical Education (Partners) requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated according to Partners policies. Others involved in the planning of this activity have no relevant financial relationships.

Primary Author

Emily Patterson, AGACNP-BC, has no relevant financial relationships to disclose.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1 hour. To successfully complete this activity and receive credit, participants must follow these steps during the period from September 29, 2025, through March 28, 2026:

  1. Login or Sign Up for an account by clicking at the top of this page.

  2. Read the target audience, learning objectives, and faculty disclosures.

  3. View and study the content in its entirety.

  4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65 and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the confirmation page. Records of all CME/CE activities completed can be found on the "My Certificates" page. There are no costs/fees for this activity.

Format

This program has been made available online.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. 

Disclaimer

Learners have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Accreditation

Joint Accreditation Statement 

 

In support of improving patient care, Partners for Advancing Clinical Education (Partners) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. 

Nursing Continuing Professional Development

The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 1 contact hour, including 1 hour of pharmacotherapy credit.

Physician Associate Continuing Medical Education

https://omni-channel-2022-assets-production.s3.amazonaws.com/editorupload/672d0c7c14643.png

Partners has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1 AAPA Category 1 CME credit. Approval is valid until March 28, 2026. PAs should only claim credit commensurate with the extent of their participation.

IPCE Credit Designation

https://omni-channel-2022-assets-production.s3.amazonaws.com/editorupload/657115052be04.jpg

This activity was planned by and for the healthcare team, and learners will receive 1 Interprofessional Continuing Education (IPCE) credit for learning and change.